Armata Pharmaceuticals (ARMP) Retained Earnings (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Retained Earnings data on file, last reported at -$616.9 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 84.53% year-over-year to -$616.9 million; the trailing twelve-month figure through Mar 2026 stood at -$616.9 million (down 84.53% YoY), and the FY2025 full-year result was $282.6 million, up 1.15% from the prior year.
• Retained Earnings slipped to -$616.9 million in Q1 2026, from $282.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $282.6 million in Q4 2025 to a low of -$616.9 million in Q1 2026.
• A 5-year average of -$79.7 million and a median of -$229.5 million in 2022 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 247.31% in 2022 and tumbled 225.92% in 2025, its largest moves.
• Tracing ARMP's Retained Earnings over 5 years: stood at -$239.8 million in 2022, then retreated by 28.8% to -$308.8 million in 2023, then surged by 190.46% to $279.4 million in 2024, then rose by 1.15% to $282.6 million in 2025, then plunged by 318.31% to -$616.9 million in 2026.
• Business Quant data shows ARMP's Retained Earnings at -$616.9 million in Q1 2026, $282.6 million in Q4 2025, and -$377.2 million in Q3 2025.